✦ LIBER ✦

Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer

✍ Scribed by Devika Gajria; Kim Feigin; Lee K. Tan; Sujata Patil; Stephanie Geneus; Maria Theodoulou; Larry Norton; Clifford A. Hudis; Tiffany A. Traina

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 172 KB
Volume: 117
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25992

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Q-TWiST analysis of ixabepilone in combi

Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer

✍ Patricia K. Corey-Lisle; Ronald Peck; Pralay Mukhopadhyay; Lucinda Orsini; Shima 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 238 KB 👁 1 views

A phase 2 trial of single-agent bevacizu

A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas

✍ Jeffrey J. Raizer; Sean Grimm; Marc C. Chamberlain; M. Kelly Nicholas; James P. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 396 KB 👁 1 views

A phase 2 trial of whole-brain radiother

A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer

✍ Philippe A. Cassier; Isabelle Ray-Coquard; Marie-Pierre Sunyach; Laurence Lancry 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 2 views

A phase I study of chronic daily dosing

A phase I study of chronic daily dosing of oral etoposide in combination with cisplatin for patients with advanced cancer

✍ Masahiro Fukuoka; Noriyuki Masuda; Shunichi Negoro; Minoru Takada; Shinzoh Kudoh 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 440 KB 👁 2 views

A phase II trial of extracorporeal plasm

A phase II trial of extracorporeal plasma immunoadsorption of patient plasma with prosorba columns for treating metastatic breast cancer

✍ David W. Fennelly; Larry Norton; Mario Sznol; Thomas B. Hakes 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 350 KB 👁 2 views

Background. Circulating immune complexes (CIC) have been implicated as a cause of malignancy-associated immunosuppression and disease progression. Previous attempts to remove CIC by pheresis or immunoadsorption over a Staphylococcus aureus protein A column have resulted in a few clinical responses,

A phase 1 trial of 2 dose schedules of A

A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer

✍ Michael S. Gordon; David Mendelson; Robert Carr; Raymond A. Knight; Rod A. Humer 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 220 KB 👁 1 views